fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Polystyrene sodium sulfonate

All products: general benefit

Kayexalate · DIN 02026961 · 1mEq/g · Oral Pd-454g Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Kayexalate · DIN 02026961 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Marketed since 2009-02-06 · brand KAYEXALATE · ATC V03AE01 POLYSTYRENE SULPHONATE · form Powder for suspension · route Oral, Rectal · ingredients SODIUM POLYSTYRENE SULFONATE 1 G/G · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $29.4175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02026961)

Source record
DIN 02026961: Kayexalate Raw flags: sec3=Y Item: 401800001; group id 551; item number 1487; lccId None; manufacturer id SAV Source form: Oral Pd-454g Pk; strength: 1mEq/g Recorded listing: General benefit Source prices (unrounded): $43.6300; ministry $29.4175 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02026961 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17752
Interchangeable products
Jamp Sodium Polystyrene Sulfonate · DIN 02497557 · $29.4175 Odan-Sodium Polystyrene Sulfonate · DIN 02473941 · $29.4175 Solystat · DIN 00755338 · $29.4175
Shortage status: resolved shortage (ended July 31, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02026961
Shortage record checked October 6, 2026

Other products in the same Health Canada class (V03AE): coverage varies; not interchangeable

  • Lanthanum (Fosrenol): not a benefit
  • Sevelamer carbonate (Renvela): not a benefit
Other drugs in the same formulary class (40:18 Potassium-Removing Resins) and how they are covered

Matched class: 40:18 Potassium-Removing Resins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 40:18 Potassium-Removing Resins

LANTHANUM

· 8 products · Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 250mg, 500mg, 750mg, 1000mg · Chew Tab

SEVELAMER CARBONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 800mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 40:18
Full class listing Related classes: 40:12 Replacement Agents, 40:28 Diuretics, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATION SOLYSTAT (sodium polystyrene sulfonate suspension) is indicated for the treatment of hyperkalemia. https://pdf.hres.ca/dpd_pm/00078001.PDF PM date: December 5, 2024 Source product: SOLYSTAT; DIN 00755338; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.